Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Hospital Discharge and Outpatient Parenteral Antibiotic Therapy | TreatmentTrends | US | 2014
Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs…
Wet Age-Related Macular Degeneration | Treatment Algorithms | Claims Data Analysis | US | 2014
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
COPD in the EU5: (How Will Prescribers and Payers Integrate Additional LABA- and LAMA-Containing Products Within Increasingly Constrained Budgets?) | Physician & Payer Forum | EU5 | 2014
Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q2 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
SPECIAL REPORT: The Launches of Opsumit, Adempas, and Orenitram into the Pulmonary Arterial Hypertension Market
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are…
Chronic Myeloid Leukemia (Prescribing Decisions and Payer Landscape in a Crowded and Changing U.S. Market) | Physician & Payer Forum | US | 2014
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
